Sacituzumab govitecan for advanced thyroid cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug called sacituzumab govitecan for people with advanced thyroid cancer that has stopped responding to standard treatments. It may be an option for those with differentiated thyroid cancer (after certain prior therapies) or anaplastic thyroid cancer (first-line or after one prior treatment).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a type of thyroid cancer that has spread or cannot be removed by surgery, and it is either differentiated thyroid cancer that no longer responds to radioactive iodine, or anaplastic thyroid cancer.
- For differentiated thyroid cancer: you have been treated with at least one of these drugs (sorafenib, lenvatinib, or cabozantinib) and no more than 3 total treatments. For anaplastic thyroid cancer: you can be starting treatment for the first time or have had only one prior treatment.
- You have a tumor sample available (or can get a new biopsy) for research.
- Your cancer has not spread to the brain.
- You are generally healthy enough to do normal daily activities (ECOG 0 or 1) and have adequate kidney, liver, and blood cell counts.
- You agree to use effective birth control if you or your partner could become pregnant.
- You are not currently taking certain other cancer treatments, and do not have a history of serious heart, lung, or bowel disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called Sacituzumab Govitecan for people with HR+/HER2- advanced or metastatic breast cancer that has stopped responding to a CDK4/6 inhibitor. It looks at whether the drug can slow down the cancer and requires you to have a tumor biopsy.
This trial tests a drug called sacituzumab govitecan in people with advanced salivary gland cancer or thyroid cancer that has spread or cannot be removed. The goal is to see if the drug can help shrink or slow down the cancer.
This trial tests a drug called sacituzumab govitecan for people with advanced thymic cancer (thymoma or thymic carcinoma) that has not responded to previous treatments. The goal is to see if the drug can shrink or slow the growth of the cancer.
This study tests a drug called sacituzumab govitecan for people with metastatic colorectal cancer who have already tried several standard treatments. It may be an option if your cancer is not MSI-H or dMMR and you haven't had irinotecan recently.
This trial tests a new drug called sacituzumab govitecan (a targeted chemotherapy) combined with hormone therapy for people whose HR-positive, HER2-negative metastatic breast cancer has worsened after treatment with a CDK4/6 inhibitor. The goal is to see if this combination can help control the cancer when standard options are limited.
This Phase 2 trial tests sacituzumab govitecan, an anti-cancer medicine, in people with recurrent or metastatic (coming back or spread) secretory gland cancers or related salivary gland cancers. It aims to see how well the treatment can shrink tumors and control disease when surgery or radiation is not a cure.
Hear when a new Differentiated Thyroid Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.